Patients with promyelocytic leukemia (French-American-British [FAB] M)
Patients with MDS must have been diagnosed as MDS by WHO (th edition) or French-American-British (FAB) classification
RAEB-t per French-American-British (FAB) classification (% to % BM blasts)
Acute promyelocytic leukemia (APL, French-American-British (FAB) subtype M), according to WHO classification.
Patients with t(;) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M-AML)
Patients with t(;) karyotypic abnormality or acute promyelocytic leukemia (French-American-British [FAB] class M-AML)
Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML, excluding acute promyelocytic leukaemia (APL, French-American British M classification):
Acute promyelocytic leukemia (M leukemia, per French-American-British classification)
Histologically confirmed diagnosis of a myelodysplastic syndrome, meeting criteria for any subtype in the French-American-British (FAB) or World Health Organization (WHO) classification systems with any International Prognostic Scoring System (IPSS) score
Diagnosis of acute promyelocytic leukemia (APL), AML - M by French American British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies
Acute promyelocytic leukemia (French-American-British [FAB] M AML)
AML, any French- American- British (FAB) subtype except M, with confirmed mutation in the NPM gene
Patients with acute promyelocytic leukemia (French-American-British [FAB] class M AML)
Diagnosis of MDS according to World Health Organization (WHO) criteria or French-American-British (FAB) classification that must be confirmed by bone marrow (BM) aspirate and/or biopsy within  weeks prior to Screening.
Patients with acute promyelocytic leukemia confirmed with t(;) (French-American-British Classification [FAB] subtype M and M variant)
Subjects with untreated AML, if not candidates for standard induction chemotherapy or with poor risk AML (i.e. preceding myelodysplastic syndromes [MDS], myeloproliferative syndromes, leukemia due to cytotoxic chemotherapy for another condition, adverse cytogenetics or complex karyotype), acute promyelocytic leukemia (French-American-British [FAB] M) is excluded
Subject has French-American-British classification (FAB) type M leukemia (acute promyelocytic leukemia) or identification of t(;).
Suspected or proven acute promyelocytic leukemia (French-American-British (FAB) M) based on morphology, immunophenotype, molecular assay, or karyotype; AML associated with t(;) karyotype, biphenotypic acute leukemia or AML with previous hematologic disorder such as chronic myelogenous leukemia or myeloproliferative neoplasms.
AML French-American-British (FAB) M in first complete remission (CR)
Morphologically confirmed diagnosis of MDS or nonproliferative CMML (that is, with white blood cells [WBC] <, per microliter [/mcL]) or low blast AML based on  of the following: French American British (FAB) Classifications:
Subjects must have relapsed/refractory AML by world health organization (WHO) classification for which no standard therapies are available or anticipated to result in a durable remission. French- American- British system (FAB) subtype M will be excluded.
Participant has acute promyelocytic leukemia (French-American-British Class M AML).
Patients with acute promyelocytic leukemia (French-American-British Cooperative group [FAB] M)
Acute promyelocytic leukaemia (French-American-British (FAB) classification subtype M).
Acute promyelocytic leukemia (French-American-British [FAB] M AML)
Diagnosis of myelodysplastic syndrome (MDS) confirmed within  weeks prior to study entry according to World Health Organization (WHO) or French-American-British (FAB) criteria; patients are either not eligible for or choose not to proceed with a stem cell transplant
Confirmed diagnosis of MDS using the World Health Organization (WHO) classification or a diagnosis of WHO myelodysplastic/ myeloproliferative neoplasm (MDS/MPN) or MDS refractory anemia with excess blast in transformation (RAEB-t) by French American British (FAB) classification (acute myeloid leukemia [AML] with -% myeloblasts by WHO classification)
Patients with known acute promyelocytic leukemia (French-American-British class M-AML)
Acute promyelocytic leukemia (French-American-British Class M AML).
MDS by World Health Organization (WHO) or French-American-British (FAB) classification
have diagnosis of AML French-American-British (FAB) classification (FAB) M (acute promyelocytic leukemia (APL))
Confirmed MDS by bone marrow biopsy according to World Health Organization (WHO) or French-American-British (FAB) criteria
Documented diagnosis of MDS (MYELODYSPLASTIC SYNDROMES), classified according to FAB (FRENCH-AMERICAN BRITISH) classification criteria